View Post

Is Breast Cancer Curable? Get the Facts

In In The News by Barbara Jacoby

From: healthline.com There’s currently no cure for metastatic breast cancer, but new treatments have improved survival rates in recent years. Researchers have gained a better understanding of the molecular and genetic characteristics of breast cancer. Improved understanding of breast cancer may help experts develop more personalized treatment plans for people with this condition. Experts now know that breast cancer isn’t …

View Post

Sanofi’s, AstraZeneca’s and Radius’ oral SERDs could establish clinical worth in ER+ breast cancer by showing similar efficacy to Faslodex, experts say

In Clinical Studies News by Barbara Jacoby

By: Manasi Vaidyacl From: clinicaltrialsarena.com Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, AstraZeneca’s Faslodex (fulvestrant) or generic aromatase inhibitors in oestrogen receptor positive (ER+) HER2-negative breast cancer, said experts. Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, …

View Post

Antibody-Drug Conjugates, TKIs Drive Improved Outcomes in HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: onclive.com The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease. The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast …

View Post

Trial Explores Preoperative Window for Amcenestrant Therapy in Early Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Denise Myshko From: onclive.com Investigators are seeking to determine whether amcenestrant (SAR439859), an investigational oral endocrine therapy, can generate meaningful antitumor activity when administered as short-term preoperative therapy to postmenopausal patients with newly diagnosed early breast cancer. The phase 2 AMEERA-4 trial (NCT04191382) is testing 2 dose levels of amcenestrant versus letrozole given for 14 days to patients with …

View Post

FDA Grants Premarket Approval to Diagnostic Breast Cancer Imaging Technology

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com The FDA’s Center for Devices and Radiological Health has granted premarket approval (PMA) to diagnostic breast cancer imaging technology developed by Seno Medical Instruments to assist in the differentiation between benign and malignant breast lesions in patients.1 By using noninvasive poto-acoustic ultrasound technology, the Imagio Breast Imaging System is able to produce data on suspicious …

View Post

Uptake of Breast Cancer Clinical Trials at Minority Serving Cancer Centers

In Clinical Studies News by Barbara Jacoby

By: DocWire News Featured Reading From: docwirenews.com ABSTRACT BACKGROUND: Most minorities receive cancer care at minority-serving hospitals (MSHs) that have been associated with disparate treatment between Black and White patients. OBJECTIVE: Our aim was to examine the uptake of clinical trials that have changed axillary management in breast cancer patients at MSH and non-MSH cancer centers. METHODS: The National Cancer …

View Post

Practicing Outside the Pharma Box in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Dawn Fallik From: onclive.com When Martine Piccart, MD, PhD, was a child, she sometimes watched her father, a gynecologist, talk to his patients. She remembers his respect for them and their families and the way he communicated, focusing on the positive but not shying away from delivering bad news. “He always took the time to explain in detail not …

View Post

Gut microbe may promote breast cancers

In Clinical Studies News by Barbara Jacoby

Source: Johns Hopkins Medicine From: eurekalert.org Short-term exposure to B. fragilis toxin leaves lasting impression in cells, increasing the risk for cancer A microbe found in the colon and commonly associated with the development of colitis and colon cancer also may play a role in the development of some breast cancers, according to new research from investigators with the Johns …

View Post

Evelo Biosciences, Inc. Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: Evelo Biosciences, Inc. From: globenewswire.com –EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503– –Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX™ product candidates to activate systemic immunity– Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine …